English | 简体中文 | 繁體中文 | 한국어 | 日本語
Sunday, 20 September 2020, 13:13 HKT/SGT
Share:
Mitsubishi Chemical: Has developed new electrolyte for Tesla. The solvents and solute are supplied from Shida Shenghua

HONG KONG, Sept 20, 2020 - (ACN Newswire) - A Mitsubishi Chemical (MTLHY) technical expert revealed that the important innovations of Tesla's new battery are the positive and negative electrodes and the new electrolyte. Mitsubishi Chemical has perfectly matched the electrolyte technology for the new battery. This electrolyte mainly uses new solutes and functional additives, which can greatly improve battery performance. The technical expert said that the solvent in the new electrolyte is still supplied by the Chinese company Shida Shenghua, and the amount of DMC in the solvent will be greatly increased. Beginning in 2017, Mitsubishi and Shida Shenghua have jointly developed a new type of solute. This product will soon be mass-produced, which can effectively increase battery cycle times and energy density.


Topic: Press release summary Sectors: Daily Finance, Chemicals, Spec.Chem, Energy, Alternatives, Daily News
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence  
Feb 9, 2026 13:28 HKT/SGT
JCB Announces Collaboration with Resorts World Sentosa in Singapore  
Monday, February 9, 2026 1:00:00 PM
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026  
Monday, February 9, 2026 10:00:00 AM
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group  
Feb 8, 2026 23:30 HKT/SGT
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.  
Feb 7, 2026 05:45 HKT/SGT
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets  
Feb 6, 2026 17:45 HKT/SGT
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share  
Feb 6, 2026 17:01 HKT/SGT
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization  
Feb 6, 2026 16:34 HKT/SGT
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis  
Feb 6, 2026 14:17 HKT/SGT
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025  
Feb 6, 2026 13:13 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575